Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

Abstract: As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diabetes mellitus (T2DM), the EMPA-REG OUTCOME trial investigated the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which has generated great interest among health care professionals. CV outcomes data for another SGLT2 inhibitor, canagliflozin, have been published recently in the CANVAS program, as have CV data from the retrospective real-world study Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL), which compared SGLT2 inhibitors with other classes of glucose-lowering drugs. This review discusses the results of these three studies and, with a focus on EMPA-REG OUTCOME, examines the possible mechanisms by which SGLT2 inhibitors may reduce CV risk in patients with T2DM.

Keywords: canagliflozin, cardiovascular outcomes, dapagliflozin, empagliflozin, mechanisms, sodium glucose cotransporter 2 inhibitors

Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals with diabetes, and reducing CVD risk is a key treatment consideration. Intensive blood glucose control to reduce hyperglycemia decreases the risk of microvascular complications in type 2 diabetes mellitus (T2DM); however, the relationship between glucose lowering and the risk of macrovascular disease is less straightforward, as demonstrated by data from trials such as UK Prospective Diabetes Study (UKPDS), Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease – Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), and Veterans Affairs Diabetes Trial (VADT). Indeed, higher rates of all-cause and cardiovascular (CV) mortality associated with intensive blood glucose lowering were reported during ACCORD, although the contribution of hypoglycemia is debated. Until 2008, clinical trials of drug therapies for T2DM typically focused on the glucose-lowering ability, via reductions in glycated hemoglobin (HbA1c), and studies of longer term CV outcomes were not required for regulatory approval in the US. However, following the 2007 publication of CV safety issues in patients with T2DM related to the use of rosiglitazone, the US Food and Drug Administration (FDA) issued guidance that required all glucose-lowering agents for the treatment of T2DM to undergo a thorough assessment on major adverse CV events (MACE).
mandating that such agents take part in a CV outcome trial (CVOT) in diabetes patients with high CV risk.11 As the purpose of the CVOT is to assess drug-specific CV safety independent of glucose-lowering efficacy, background glucose-lowering agents (other than the class of active comparator being investigated) are permitted in all treatment arms, per the standard of care.12 Data from a number of CVOTs in glucose-lowering agents have been completed (Table 1),13–26 and others are underway (Table 2).27,28 Results from several CVOTs in glucose-lowering agents have demonstrated CV safety and met the criteria for non-inferiority versus placebo, but have not shown superiority, namely,

Table 1 Completed CV outcome trials of glucose-lowering drugs in patients with T2DM

<table>
<thead>
<tr>
<th>Trial name (publication year)</th>
<th>Major inclusion criteria</th>
<th>Number of patients randomized</th>
<th>Median follow-up, years</th>
<th>Intervention</th>
<th>Primary outcome data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DPP-4 inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAVOR-TIMI 53 (2013)13</td>
<td>≥40 years + history of established CVD; males ≥55 years or females ≥60 years + risk factors for vascular disease</td>
<td>16,492</td>
<td>2.1</td>
<td>Saxagliptin versus placebo</td>
<td>Composite: CV death, non-fatal MI, or non-fatal ischemic stroke; HR 1.00 (95% CI: 0.89, 1.12); p = 0.99 for superiority; p &lt; 0.001 for non-inferiority</td>
</tr>
<tr>
<td>EXAMINE (2013)14</td>
<td>Acute coronary event within previous 15–90 days</td>
<td>5380</td>
<td>1.8</td>
<td>Alogliptin versus placebo</td>
<td>Composite: CV death, non-fatal MI, or non-fatal stroke; HR 0.96 (upper bound of one-sided repeated CI: 1.16); p &lt; 0.001 for non-inferiority</td>
</tr>
<tr>
<td>TECOS (2014)15</td>
<td>HbA1c 6.5%–8.0%, ≥50 years; established CVD</td>
<td>14,671</td>
<td>3.0</td>
<td>Sitagliptin versus placebo</td>
<td>Composite: CV death, non-fatal MI, non-fatal stroke, or hospitalization for UA; HR 0.98 (95% CI: 0.88, 1.09); p &lt; 0.001 for non-inferiority</td>
</tr>
<tr>
<td><strong>GLP-1 receptor agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ELIXA (2015)16</td>
<td>HbA1c 5.5%–11.0%; acute coronary event ≤180 days prior to screening</td>
<td>6068</td>
<td>2.1</td>
<td>Lixisenatide versus placebo</td>
<td>Composite: CV death, non-fatal MI, non-fatal stroke, or hospitalization for UA; HR 1.02 (95% CI: 0.89, 1.17); p = 0.81 for superiority; p &lt; 0.001 for non-inferiority</td>
</tr>
<tr>
<td>LEADER (2016)17</td>
<td>HbA1c ≥7.0%; ≥50 years + CVD; ≥60 years + ≥1 CV risk factor</td>
<td>9340</td>
<td>3.8</td>
<td>Liraglutide versus placebo</td>
<td>Composite: CV death, non-fatal MI, or non-fatal stroke; HR 0.87 (95% CI: 0.78, 0.97); p = 0.01 for superiority; p &lt; 0.001 for non-inferiority</td>
</tr>
<tr>
<td>SUSTAIN-6 (2016)18</td>
<td>HbA1c ≥7.0%; ≥50 years + CVD; ≥60 years + ≥1 CV risk factor</td>
<td>3297</td>
<td>2.1</td>
<td>Semaglutide 0.5 mg versus semaglutide 1.0 mg versus placebo</td>
<td>Composite: CV death, non-fatal MI, or non-fatal stroke; HR 0.74 (95% CI: 0.58, 0.95); p = 0.02 for superiority; p &lt; 0.001 for non-inferiority</td>
</tr>
</tbody>
</table>
| EXSCEL (2017)19              | HbA1c ≥6.5%; 40 years + CVD history | 14,752                       | 3.2                     | Subcutaneous injections of extended-release exenatide 2 mg versus placebo (once weekly) | Composite: CV death, non-fatal MI, or non-fatal stroke; HR 0.91 (95% CI: 0.83, 1.00); p = 0.06 for superiority; p < 0.001 for non-inferiority (Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Trial name (publication year)</th>
<th>Major inclusion criteria</th>
<th>Number of patients randomized</th>
<th>Median follow-up, years</th>
<th>Intervention</th>
<th>Primary outcome data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin DEVO (2017)¹¹</td>
<td>HbA1c ≥7.0% or &lt;7.0% with basal insulin 20 U/day; ≥50 years + CVD or renal disease; ≥60 years + CV risk factors</td>
<td>7637</td>
<td>2.0</td>
<td>Insulin degludec versus insulin glargine</td>
<td>Composite: CV death, non-fatal MI, or non-fatal stroke; degludec versus glargine; HR 0.91 (95% CI: 0.78, 1.06); p &lt; 0.001 for non-inferiority in a one-sided test</td>
</tr>
<tr>
<td>PPAR-gamma agonists TOSCA.I [2017]²²</td>
<td>HbA1c ≥7.0% and ≤9.0%; metformin monotherapy</td>
<td>3028</td>
<td>4.75</td>
<td>Pioglitazone versus sulfonylurea</td>
<td>Composite: death, non-fatal MI, non-fatal stroke or urgent coronary revascularization; HR 0.96 (95% CI: 0.74, 1.26); p = 0.79</td>
</tr>
<tr>
<td>SGLT2 inhibitors EMPA-REG OUTCOME (2015)²³</td>
<td>HbA1c 7.0%–9.0% (if drug naive) or 7.0%–10.0% (if receiving stable glucose-lowering medication &gt;12 weeks pre-randomization); established CVD</td>
<td>7020</td>
<td>3.1</td>
<td>Empagliflozin 10 mg versus empagliflozin 25 mg versus placebo (analyzed as empagliflozin pooled vs placebo)</td>
<td>Composite: CV death, non-fatal MI, or non-fatal stroke; HR 0.86 (95.02% CI: 0.74, 0.99); p = 0.04 for superiority; p &lt; 0.001 for non-inferiority</td>
</tr>
<tr>
<td>CANVAS Program (2017)[4] CANVAS + CANVAS-R</td>
<td>HbA1c 7.0%–10.5%; ≥30 years history of CVD, or ≥50 years high risk of CVD</td>
<td>10,142 (CANVAS 4330 + CANVAS-R 5812)</td>
<td>2.4</td>
<td>Canagliflozin 100 mg versus canagliflozin 300 mg versus placebo</td>
<td>Composite: CV death, non-fatal MI, and non-fatal stroke; HR 0.86 (95% CI: 0.75, 0.97); p = 0.02 for superiority; p &lt; 0.001 for non-inferiority</td>
</tr>
<tr>
<td>CVD-REAL² (2017)²⁵</td>
<td>T2DM; new users of SGLT2 inhibitors or other GLD (Not randomized; observational)</td>
<td>309,056</td>
<td>Retrospective registries study</td>
<td>SGLT2 inhibitors versus other classes of GLD</td>
<td>Hospitalization for heart failure; HR 0.61 (95% CI: 0.51, 0.73); p &lt; 0.001</td>
</tr>
<tr>
<td>CVD-REAL Nordic² (2017)²⁶</td>
<td>T2DM; new users of SGLT2 inhibitors or other GLD (Not randomized; observational)</td>
<td>91,320</td>
<td>Retrospective registries study</td>
<td>SGLT2 inhibitors versus other classes of GLD</td>
<td>CV death; HR 0.53 (95% CI: 0.40, 0.71); p &lt; 0.0001; Composite: CV death, MI, or stroke; HR 0.78 (95% CI: 0.69, 0.87); p &lt; 0.0001; Hospitalization for heart failure; HR 0.70 (95% CI: 0.61, 0.81); p &lt; 0.0001</td>
</tr>
</tbody>
</table>

Notes: Bold text indicates superiority in reducing risk of major adverse CV events (MACE) demonstrated versus placebo. SAVOR-TIMI 53, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction; EXAMINE, Evaluation of Cardiovascular Outcomes with Alogliptin versus Standard of Care; TECOS, Trial Evaluating Cardiovascular Outcomes with Sitagliptin; LEADER, Liraglutide effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results SUSTAIN-6, Trial to Evaluate Cardiovascular and Other Long-term Outcomes in Subjects With Type 2 Diabetes on Semaglutide in Subjects with Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering Trial; FREEDOM CVD, A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650; DEVOTE, A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events; TOSCA.I, Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial; EMPA-REG OUTCOME, Empagliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients; CANVAS, Canagliflozin Cardiovascular Assessment Study, + CANVAS-R, A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus; CVD-REAL, Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (listed by alphabetical order of drug class and then by chronological order of primary publication). CV-REAL is included for completeness, as the data support the CV benefits of SGLT2 inhibitors in T2DM, as demonstrated in EMPA-REG OUTCOME and the CANVAS Program. Abbreviations: CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase-4; GLD, glucose-lowering drug; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HR, hazard ratio; MI, myocardial infarction; PPAR, peroxisome proliferator-activated receptor; SGLT2, sodium glucose cotransporter-2; T2DM, type 2 diabetes mellitus; UA, unstable angina.

Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53),¹³ Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE),¹⁴ Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS),¹⁵ Evaluation of LIXisenatide in Acute Coronary Syndrome (ELIXA),¹⁶ and Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL);¹⁷ in addition, Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial (TOSCA.I) demonstrated no significant differences between treatment groups in the prespecified CV outcomes.²² Evidence that a
### Table 2: Ongoing drug-specific CV outcome trials in patients with T2DM

<table>
<thead>
<tr>
<th>Trial acronym (ClinicalTrials.gov identifier)</th>
<th>Patient population</th>
<th>Estimated enrollment, N&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Intervention</th>
<th>Primary outcome</th>
<th>Estimated end date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DPP-4 inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARMELINA (NCT01897532)</td>
<td>HbA1c 6.5%–10%; ≥18 years; high CV risk defined by micro- or macroalbuminuria and previous macrovascular disease and/or impaired renal function with predefined UACR</td>
<td>7053</td>
<td>Linagliptin versus placebo</td>
<td>Composite: CV death, non-fatal MI, non-fatal stroke, or hospitalization for UA</td>
<td>December 2017</td>
</tr>
<tr>
<td>CAROLINA (NCT01243424)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>HbA1c 6.5%–8.5% (SU naive) or 6.5%–7.5% (previous SU exposure); 40–85 years; CV risk</td>
<td>6072</td>
<td>Linagliptin versus glimepiride</td>
<td>Composite: CV death, non-fatal MI, non-fatal stroke, or hospitalization for UA</td>
<td>March 2019</td>
</tr>
<tr>
<td><strong>GLP-1 receptor agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REWIND (NCT01394952)</td>
<td>HbA1c ≤9.5%; 50 years + CVD; 55 years + subclinical CVD; ≥60 years + CV risk factors</td>
<td>9622</td>
<td>Dulaglutide versus placebo</td>
<td>Composite: CV death, non-fatal MI, or non-fatal stroke</td>
<td>July 2018</td>
</tr>
<tr>
<td>HARMONY Outcomes (NCT02465515)</td>
<td>HbA1c ≤7.0%; 40 years + CVD</td>
<td>9400</td>
<td>Albiglutide versus placebo</td>
<td>Composite: CV death, MI, or stroke</td>
<td>May 2019</td>
</tr>
<tr>
<td><strong>SGLT2 inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DECLARE-TIMI 58 (NCT01730534)</td>
<td>HbA1c criteria not stated; ≥40 years; known CVD or high CV risk</td>
<td>17,276</td>
<td>Dapagliflozin 10 mg versus placebo</td>
<td>Composite: CV death, MI, or stroke</td>
<td>April 2019</td>
</tr>
<tr>
<td>CREDENCE (NCT02065791)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>HbA1c 6.5%–12.0%; ≥30 years; eGFR ≥30–90 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;; stable dose ACE inhibitor or ARB; UACR &gt;300–5500 mg/g</td>
<td>4200</td>
<td>Canagliflozin 100 mg versus placebo</td>
<td>Composite: end-stage kidney disease, doubling of serum creatinine, renal or CV death</td>
<td>June 2019</td>
</tr>
<tr>
<td>VERTIS CV trial (NCT01986881)</td>
<td>HbA1c 7.0%–10.5%; ≥40 years; history or evidence of atherosclerotic vascular disease</td>
<td>8000</td>
<td>Ertugliflozin 5 mg versus ertugliflozin 15 mg versus placebo</td>
<td>Composite: CV death, non-fatal MI, or non-fatal stroke</td>
<td>October 2019</td>
</tr>
</tbody>
</table>

**Notes:** REWIND, Researching Cardiovascular Events With a Weekly Incretin in Diabetes (https://clinicaltrials.gov/ct2/show/NCT01394952); HARMONY Outcomes, Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus (https://clinicaltrials.gov/ct2/show/record/NCT02465515); CAROLINA, Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (https://clinicaltrials.gov/ct2/show/NCT01243424); CARMELINA, Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes (https://clinicaltrials.gov/ct2/show/NCT01897532); CREDENCE, Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (https://clinicaltrials.gov/ct2/show/NCT02065791); DECLARE-TIMI 58, Dapagliflozin Effects on Cardiovascular Events – Thrombolysis in Myocardial Infarction (https://clinicaltrials.gov/ct2/show/NCT01730534); VERTIS CV, Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease (https://clinicaltrials.gov/ct2/show/NCT01986881) (listed by alphabetical order of drug class and then by chronological order of estimated study end date).<sup>a</sup>Citation listed if study details were published. <sup>b</sup>Data per ClinicalTrials.gov.

**Abbreviations:** ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CV, cardiovascular; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; MI, myocardial infarction; SGLT2, sodium glucose cotransporter 2; SU, sulfonylurea; T2DM, type 2 diabetes mellitus; UA, unstable angina; UACR, urine albumin to creatinine ratio.

A glucose-lowering agent could lower the risk of CV events, ie, show superiority in reducing the risk of MACE in diabetes patients with high CV risk, has been demonstrated in four CVOTs in T2DM to date (see also Table 3).<sup>17,18,23,24,29,30,19</sup> The first of these was EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME)<sup>18</sup>, which investigated the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin.<sup>21</sup> This was followed by CVOTs of the glucagon-like peptide-1 receptor agonists, liraglutide (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER])<sup>17</sup> and semaglutide (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes [SUSTAIN-6]).<sup>18</sup> Most recently, CVOT data from another SGLT2 inhibitor, canagliflozin, have been published...
in the CANagliflozin CardioVascular Assessment Study (CANVAS Program) report, and these data support the CV benefits in T2DM patients observed with this drug class.24 A further report of “real-world” data for CV outcomes in T2DM patients receiving SGLT2 inhibitors was published recently, when Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL) demonstrated that SGLT2 inhibitors reduced the risk of hospitalization for heart failure when compared with other classes of glucose-lowering drugs.25,26 It should be noted that the CVD-REAL study differs from the aforementioned trials in that it was a non-randomized registry study, rather than a dedicated CVOT; nonetheless, it is included herein for completeness, as it provides additional CV outcomes data for US-approved SGLT2 inhibitors.

This report discusses the results of EMPA-REG OUTCOME, the CANVAS Program, and CVD-REAL, and – with a focus on EMPA-REG OUTCOME – examines the possible mechanisms by which SGLT2 inhibitors may reduce CV risk in patients with T2DM.

Summary of results from EMPA-REG OUTCOME

EMPA-REG OUTCOME was the first CVOT of an SGLT2 inhibitor to publish final data.23 Briefly, this was a multicenter, randomized, double-blind, placebo-controlled trial to assess the effect on CV events of once-daily empagliflozin (10 mg or 25 mg) versus placebo administered in addition to standard care in adults with T2DM and established CVD.23 A total of 7020 patients with T2DM were randomized, and major inclusion criteria included established CVD (defined as previous myocardial infarction [MI], coronary artery disease, unstable angina, stroke, or occlusive peripheral arterial disease), body mass index of 45 kg/m2 or less, and estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2. The mean age of the patients was 63 years, 28% were female,
57% had been diagnosed with T2DM for at least 10 years, and 99% had established CVD. The patient population was well treated for CV risk factors; at baseline, ~81% of patients were receiving angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs), ~65% were receiving beta-blockers, and ~43% were receiving diuretics.23 The primary outcome was a composite, known as 3-point MACE, consisting of death from CV causes, non-fatal MI, or non-fatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary outcome was a composite of the primary outcome plus hospitalization for unstable angina. The median duration of treatment was 2.6 years, and the median observation time was 3.1 years.23 Results demonstrated that the primary outcome occurred in significantly fewer patients in the empagliflozin group versus the placebo group (10.5% vs 12.1%, respectively; hazard ratio [HR] 0.86; 95.02% confidence interval [CI] 0.74–0.99; p = 0.04 for superiority) (Table 4),23 equating to a 14% relative risk reduction (RRR) in 3-point MACE. When the MACE components were analyzed separately, there was a 38% RRR in CV death with empagliflozin compared with placebo, a 35% RRR for hospitalization for heart failure, and a 32% RRR in all-cause mortality, all of which were statistically significant.23 However, there was no significant difference in the rates of non-fatal MI or non-fatal stroke.23 In analyses of subgroups according to baseline characteristics, there was some heterogeneity for the primary outcome, but reductions in the risk of CV death were consistent across subgroups.23 In terms of safety, participants receiving empagliflozin had an increased rate of genital infection (6.4% vs 1.8% for placebo) and urosepsis (0.4% vs 0.1% for placebo), but there were no between-group differences in other adverse events (including confirmed hypoglycemic events, acute renal failure, diabetic ketoacidosis, thromboembolic events, bone fracture, volume depletion events, complicated urinary tract infection, or pyelonephritis).23

Differences in the primary endpoint between empagliflozin and placebo during EMPA-REG OUTCOME were driven by the significant reduction in CV death.23 The reduction in the risk of CV death occurred early in the study (the event curve for empagliflozin separated from placebo within 12 weeks of starting study drug treatment) and continued throughout the study period.23 A similar observation was made for the risk reduction in all-cause mortality.23 This is earlier than might be predicted for glucose-lowering effects, based on the observed between-group differences in HbA1c values (0.45% at 90 weeks and 0.28% at 204 weeks).31 The early reduction in CV death, occurring without significant reductions in non-fatal MI or non-fatal stroke, suggests that empagliflozin could improve CV survival rather than slow atherosclerosis and/or prevent atherosclerotic events.31 This early separation of event curves corresponds with results of the study.

### Table 4 EMPA-REG OUTCOME: primary and selected secondary CV outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Empagliflozin pooled (N = 4687)</th>
<th>Placebo (N = 2333)</th>
<th>Hazard ratio (95% CI)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median treatment and observation time, years (interquartile range)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>p-valuea</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>2.6 (2.0–3.4)</td>
<td>2.6 (1.8–3.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation</td>
<td>3.2 (2.2–3.6)</td>
<td>3.1 (2.2–3.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death from CV causes, non-fatal MI, or non-fatal stroke</td>
<td>490 (10.5)</td>
<td>282 (12.1)</td>
<td>0.86 (0.74, 0.99)b</td>
<td>Non-inferiority &lt;0.001</td>
</tr>
<tr>
<td>Key secondary outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death from CV causes, non-fatal MI, non-fatal stroke, or hospitalization for UA</td>
<td>599 (12.8)</td>
<td>333 (14.3)</td>
<td>0.89 (0.78, 1.01)c</td>
<td>Non-inferiority &lt;0.001</td>
</tr>
<tr>
<td>Death from any cause</td>
<td>269 (5.7)</td>
<td>194 (8.3)</td>
<td>0.68 (0.57, 0.82)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Death from CV causes</td>
<td>172 (3.7)</td>
<td>137 (5.9)</td>
<td>0.62 (0.49, 0.77)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fatal or non-fatal MI excluding silent MI</td>
<td>223 (4.8)</td>
<td>126 (5.4)</td>
<td>0.87 (0.70, 1.09)</td>
<td>0.23</td>
</tr>
<tr>
<td>Non-fatal MI excluding silent MI</td>
<td>213 (4.5)</td>
<td>121 (5.2)</td>
<td>0.87 (0.70, 1.09)</td>
<td>0.22</td>
</tr>
<tr>
<td>Hospitalization for UA</td>
<td>133 (2.8)</td>
<td>66 (2.8)</td>
<td>0.99 (0.74, 1.34)</td>
<td>0.97</td>
</tr>
<tr>
<td>Fatal or non-fatal stroke</td>
<td>164 (3.5)</td>
<td>69 (3.0)</td>
<td>1.18 (0.89, 1.56)</td>
<td>0.26</td>
</tr>
<tr>
<td>Non-fatal stroke</td>
<td>150 (3.2)</td>
<td>60 (2.6)</td>
<td>1.24 (0.92, 1.67)</td>
<td>0.16</td>
</tr>
<tr>
<td>Hospitalization for heart failure</td>
<td>126 (2.7)</td>
<td>95 (4.1)</td>
<td>0.65 (0.50, 0.85)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Notes: *One-sided p-values are shown for tests of non-inferiority; two-sided p-values are shown for tests of superiority. 95.02% CI.
Abbreviations: CI, confidence interval; CV, cardiovascular; EMPA-REG OUTCOME, Empagliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients; MI, myocardial infarction; UA, unstable angina.
observed with aldosterone antagonists in heart failure studies such as EPLERENONE Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Conversely, changes in CV outcomes with tiraglutide versus placebo in the LEADER trial were not observed until approximately 12 months of follow-up.

The reduction in hospitalization for heart failure with empagliflozin was an unexpected result during EMPA-REG OUTCOME, and may suggest that this agent could affect ventricular function in addition to its diuretic effects. Subsequent data analysis showed a consistent benefit of empagliflozin therapy in those with and without heart failure at baseline. However, it is important to note that the diagnosis of heart failure at baseline in EMPA-REG OUTCOME was based on investigators’ clinical assessment without measuring biomarkers or ejection fraction (~10% of patients were diagnosed with heart failure at baseline); accordingly, it is possible that a further proportion of patients in the study may have had mild or subclinical heart failure, silent ischemia, or undiagnosed diabetic cardiomyopathy. As with the observed reduction in CV death, the effect of empagliflozin on heart failure hospitalization occurred very early in the trial. Again, this is suggestive of a non-atherosclerotic driven effect. Potential contributory factors include reduced cardiac preload and afterload, reduced plasma volume, osmotic diuresis, reduced arterial stiffness, and decreased double product or rate pressure product (heart rate multiplied by systolic blood pressure [BP]), as well as reductions in body weight, BP, and hyperglycemia. Other mechanisms may also have a role, although supporting data are limited at present. For example, increased activity of the sodium/hydrogen exchanger (NHE) is associated with heart failure; empagliflozin was shown recently to directly inhibit the NHE in isolated animal ventricular myocytes, independent of SGLT2 activity. Furthermore, in a small study (N = 10) of patients with T2DM and established CVD, short-term empagliflozin treatment was associated with a significant reduction in left ventricular mass index and improved diastolic function. Additional studies are needed to expand on these sets of preliminary data.

Summary of results from CANVAS Program

The CANVAS Program was an integrated analysis of data from two CVOTs, CANVAS and CANVAS-Renal Endpoints (CANVAS-R), and involved 10,142 patients with T2DM and high CVD risk or established CVD who were randomized to receive canagliflozin (100 mg, 300 mg, or 100–300 mg up-titrated, daily) versus placebo. Patients had a mean age of 63 years, 36% were female, mean duration of diabetes was 13.5 years, and 66% had a history of CVD at baseline. Approximately 80% of patients were prescribed renin-angiotensin-aldosterone system (RAAS) inhibitors at baseline, 53% were prescribed beta-blockers, and 44% were prescribed diuretics. The primary outcome was 3-point MACE. Sequential conditional hypothesis testing was planned for the secondary outcomes of all-cause death, CV death, progression of albuminuria, and the composite of CV death and hospitalization for heart failure; however, if sequential testing was not significant for all of these outcomes, the remaining outcomes were scheduled for assessment as exploratory variables in the integrated dataset.

Mean follow-up was 290–298 weeks for CANVAS and 108 weeks for CANVAS-R; overall mean follow-up was 188 weeks (median ~126 weeks). There was a 14% reduction in the risk of CV events for canagliflozin versus placebo (3-point MACE, 26.9 vs 31.5 participants per 1000 patient-years; HR 0.86; 95% CI: 0.75–0.97; p = 0.02 for superiority); however, the effects of the individual MACE components did not reach statistical significance. CANVAS Program data also showed that patients treated with canagliflozin had a lower risk of hospitalization for heart failure versus placebo; however, this was tested in an exploratory manner. Although the primary endpoint result of the CANVAS Program was similar to that reported in EMPA-REG OUTCOME, there were some noteworthy differences between the efficacy results of these trials; specifically, the significant reductions in CV death and all-cause death demonstrated with empagliflozin were not shown with canagliflozin. Commentators suggested that this may be due to the fact that only two-thirds of the patients in the CANVAS Program had established CVD (vs all patients in EMPA-REG OUTCOME). Canagliflozin treatment was associated with adverse events previously reported with SGLT2 inhibitors, such as genital infection, volume depletion, and diuresis; however, there was no increased risk in other adverse events versus placebo (including hypoglycemic events, hyperkalemia, acute kidney injury, pancreatitis, malignancies, diabetic ketoacidosis, or venous thromboembolism). An increased risk of amputation was reported for canagliflozin versus placebo (6.3 vs 3.4 participants per 1000 patient-years, respectively; HR 1.97; 95% CI: 1.41, 2.75), primarily occurring at the level of the toe or metatarsal; and there was a higher rate of bone fracture (15.4 vs 11.9 participants with fracture per 1000 patient-years, respectively; HR 1.26; 95% CI: 1.04, 1.52).
Summary of results from CVD-REAL

Data from the first large, real-world study of patients with T2DM, both with and without established CVD, were recently published in the CVD-REAL study, which compared CV outcomes in patients newly receiving SGLT2 inhibitors versus other classes of glucose-lowering drugs.25,26 The aims of the study – a retrospective observational cohort analysis – were to determine if the findings of EMPA-REG OUTCOME could be applied to real-world clinical practice, and to investigate whether similar benefits could be expected in T2DM patients with a broader CV risk profile.25 Following propensity score matching, 154,528 patients who were new users of an SGLT2 inhibitor were selected from patient registry datasets from six countries (US, Germany, Sweden, Norway, Denmark, and UK) and matched (1:1) with patients who were new users of other glucose-lowering drugs.25 Patients had a mean age of 57 years, 44% were female, and 13% had established CVD. At baseline, approximately 80% of all patients received BP-lowering therapy (of which 75% received ACE inhibitors or ARBs), 67% received statins, and 79% received metformin. The primary outcome was the risk of hospitalization for heart failure (inpatient or outpatient visit); secondary outcomes included all-cause mortality and a composite endpoint of hospitalization for heart failure or all-cause mortality. Safety was not examined. Mean duration of follow-up for hospitalization for heart failure was 239 days in the SGLT2 inhibitor group and 211 days in the other glucose-lowering drugs group. Treatment with an SGLT2 inhibitor versus other glucose-lowering drugs was associated with a 39% RRR in hospitalization for heart failure, a 51% RRR in all-cause mortality, and a 46% RRR in the composite endpoint.25 As 87% of patients did not have established CVD, the investigators concluded that these data suggest possible CV benefits for a broad population of patients with T2DM.25 (However, this would contradict the suggested explanation for observed differences between EMPA-REG OUTCOME and the CANVAS Program as being related to the different proportion of patients with established CVD in each study.) Also, as there was a lack of significant heterogeneity in the data across the six countries, despite geographic variations in individual SGLT2 inhibitor use (United States: canagliflozin ~76%, dapagliflozin ~19%, empagliflozin ~5%; European countries combined: canagliflozin ~2%, dapagliflozin ~92%, empagliflozin ~6%), these data appear to be related to the SGLT2 inhibitor drug class rather than to an individual SGLT2 inhibitor agent.25

The CVD-REAL Nordic sub-study (carried out in Sweden, Norway, and Denmark) also published CV morbidity and mortality data recently.26 The CV outcomes investigated were CV mortality, 3-point MACE, hospitalization for heart failure (inpatient or outpatient visit), non-fatal MI, non-fatal stroke, and atrial fibrillation. After propensity score matching (1:3), 91,320 patients were included in either the new users of SGLT2 inhibitors group (n = 22,830) or the new users of other glucose-lowering drugs group (n = 68,490). Patients had a mean age of 61 years, 40% were female, time since first glucose-lowering drug treatment was 7–8 years, baseline prevalence of CV and microvascular comorbidity was 25% for each, and the prevalence of baseline medications was similar to that described in the CVD-REAL study. Mean follow-up was 0.9 years. Dapagliflozin use accounted for 94% of the total SGLT2 inhibitor exposure, with 5% for empagliflozin and 1% for canagliflozin.26 Compared with other classes of glucose-lowering drugs, treatment with an SGLT2 inhibitor was associated with a 47% RRR in CV mortality, 22% RRR in MACE, and 30% RRR in hospitalization for heart failure.26

Although the data from CVD-REAL are supportive for SGLT2 inhibitor-associated CV benefits, it must be noted that real-world observational studies do not provide the same level of evidence as randomized controlled trials, due to factors such as bias (eg, immortal time bias, channeling, differences in patient selection, treatment adherence, assessment of outcomes, and/or withdrawals from the study), incomplete or inaccurate data, and/or lack of standardization of outcomes measures across all study sites.38 In addition, biases in the real-world setting may be overlooked because of the large number of participants in such studies. Several other limitations and observations of the CVD-REAL study have been discussed,39 including the fact that although >90% of SGLT2 inhibitor group patients in CVD-REAL Nordic were exposed to dapagliflozin, CV safety and any CV benefits of this agent will only be established following the final results of the DECLARE-TIMI 58 CVOT, which are due in 2019.39

Effect of SGLT2 inhibitors on CV risk factors

The available literature on the associated beneficial effects of empagliflozin on CV risk factors is larger than that for the other SGLT2 inhibitors; therefore, the following discussion relates primarily to empagliflozin and EMPA-REG OUTCOME.
Understanding how SGLT2 inhibitors affect various CV risk factors may provide an explanation of the possible mechanisms responsible for the CV benefits observed with SGLT2 inhibitors. SGLT2 inhibitors are the most recent class of glucose-lowering agents to gain regulatory approval for use in the treatment of patients with T2DM, and their mechanism of action is well documented. Briefly, SGLT2 inhibitors reduce renal glucose reabsorption and increase urinary glucose excretion, thereby lowering elevated blood glucose levels. SGLT2, a sodium glucose cotransporter protein, is responsible for the majority (~97%) of glucose reabsorption in the kidney and is located in the early proximal tubule; its family member SGLT1 has a minor role in renal glucose reabsorption. Studies using diabetic rodent models reported increased renal SGLT2 expression, resulting in elevated glucose reabsorption and preservation of hyperglycemia. Pharmacologic inhibition of renal SGLT2 reduces the capacity for renal glucose reabsorption by approximately 50%, thus reducing the degree of hyperglycemia. The associated calorie loss contributes to reduced body weight, which together with modest diuresis and natriuresis lowers BP. In addition to empagliflozin, three other SGLT2 inhibitors – canagliflozin, dapagliflozin, and ertugliflozin – were approved by the FDA. Empagliflozin, canagliflozin, and dapagliflozin have marketing approval in the European Union as well as in other parts of the world.

One additional SGLT2 inhibitor – sotagliflozin (a dual SGLT1/SGLT2 inhibitor) – is in advanced stages of clinical development in the US and Europe; and three further agents – ipragliflozin, tofogliflozin, and luseogliflozin – have been approved in Japan. Data from clinical trials of canagliflozin, dapagliflozin, and empagliflozin have established that these agents, given as monotherapy or in combination with other glucose-lowering agents, improve blood glucose control and are also associated with modest reductions in body weight and BP. These and other effects reported during clinical trials of SGLT2 inhibitors are discussed in following sections with regard to possible explanations for the benefits to CV risk observed during EMPA-REG OUTCOME, which do not currently appear to be strongly related to effects on atherosclerosis.

Glucose control

SGLT2 inhibitors were designed to reduce hyperglycemia in T2DM, as demonstrated by a meta-analysis of 34 randomized controlled trials (duration ≥12 weeks) of SGLT2 inhibitors that reported a mean decrease in HbA1c of 0.69% and in fasting plasma glucose of 0.9 mmol/L (16.2 mg/dL) versus placebo. However, the observed placebo-subtracted decrease in HbA1c during EMPA-REG OUTCOME was modest (~0.3%–0.4%) and comparable to that recorded in other CVOTs that reported neutral effects on CV outcomes (such as SAVOR-TIMI 53, EXAMINE, TECOS, and ELIXA). It should be noted that EMPA-REG OUTCOME was designed to have equivalent glucose control across treatment arms, allowing evaluation of CV safety to be independent of this factor. Thus, the early beneficial effects of empagliflozin on CV events observed in EMPA-REG OUTCOME are unlikely to be due to improvements in glucose lowering.

Body weight and adiposity

SGLT2 inhibitor-induced urinary glucose excretion is associated with an expected daily calorie loss of ~240–320 kilocalories (based on a daily urinary glucose excretion of ~60–80 g). Longer term (≥1 year) clinical trials of SGLT2 inhibitors have shown that the caloric loss contributed by urinary glucose excretion is associated with modest decreases in body weight, mainly due to reduced body fat content (visceral and subcutaneous). Metabolic effects associated with SGLT2 inhibitors – including increased lipolysis, fat oxidation, and ketogenesis, plus decreased insulin secretion and increased glucagon release – also contribute to loss of fat and body weight. The reduction in the visceral adiposity associated with SGLT2 inhibitors is of interest as the abnormal adipocyte biology and altered production of adipokines associated with obesity have a role in increasing the metabolic risk for T2DM, CV complications, and overall mortality.

Energy metabolism and substrate utilization

SGLT2 inhibitors cause a shift in the substrate for energy metabolism from carbohydrate to lipid utilization, and are also associated with decreased insulin secretion and increased glucagon release (ie, insulin-to-glucagon ratio decreases), thus promoting metabolic conditions for increased ketone production. In studies using rat models, ketones were shown to be a more efficient fuel source than fatty acids or glucose for the heart, and increased ketone levels were associated with increased cardiac efficiency at the mitochondrial level. In a diabetic rat model, SGLT2 inhibitors did not decrease blood levels of total ketones (ie, acetoacetate and beta-hydroxybutyrate). Therefore, it is conceivable that changes in metabolic substrate utilization associated with SGLT2 inhibitors could confer benefits to cardiac function, particularly in a failing heart, and contribute to the cardio-protective effects observed in EMPA-REG OUTCOME.
Lipid profiles
SGLT2 inhibitor clinical trials have reported small increases in the concentration of both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and these changes were also observed during EMPA-REG OUTCOME. However, no significant changes in the LDL-C/HDL-C ratio were observed. Hemoconcentration associated with SGLT2 inhibitor treatment has been suggested as a possible mechanism to explain the increases in LDL-C and HDL-C. Recent pre-clinical data revealed that empagliflozin elevated LDL-C levels in fasting conditions via reduced LDL-C catabolism; the proposed explanation for this was a “starvation shift” in energy metabolism (caused by calorie loss from SGLT2 inhibition-associated urinary glucose excretion) from carbohydrate to lipid utilization that moderately increased ketone production and hepatic cholesterol synthesis, and resulted in increased LDL-C levels. However, the clinical relevance of these changes in LDL-C and HDL-C regarding CV outcomes is unclear at present, given that increased LDL-C is a risk factor for coronary heart disease.

Uric acid
SGLT2 inhibitors are associated with small reductions in serum uric acid levels, as observed during EMPA-REG OUTCOME. Higher serum uric acid levels are associated with CV risk factors such as hypertension and obesity, and also with an increased risk of incident coronary heart disease, heart failure, and atrial fibrillation; however, it is unclear whether uric acid is a risk factor and/or a causative agent. The mechanism by which SGLT2 inhibitors decrease uric acid concentration is unknown, but may involve a direct effect on the kidneys via the uric acid transport system or an indirect effect arising from reduced sodium reabsorption in the proximal tubule.

Blood pressure
Clinical trials of SGLT2 inhibitors have reported modest reductions in systolic BP (3–5 mm Hg) and diastolic BP (2–3 mm Hg) without compensatory tachycardia. This was confirmed in studies of SGLT2 inhibitors in patients with T2DM and hypertension that assessed BP via 24-hour ambulatory monitoring, in which significant reductions in mean systolic and diastolic BP occurred by week 12. In EMPA-REG OUTCOME, a decrease in systolic and diastolic BP of approximately 5 and 2 mm Hg, respectively, was observed. Nevertheless, reduced rates of CV events have been reported with even small BP reductions. The mechanistic basis for the observed BP reduction with SGLT2 inhibitors is not fully understood, but proposed mechanisms include diuretic effects, reduction in weight, and decreased arterial stiffness. Lowering BP by one or a combination of these mechanisms would be expected to provide a rapid and beneficial effect on a patient with heart failure. This would be consistent with the reduction in heart failure hospitalization risk and with the early event curve separation observed in EMPA-REG OUTCOME. Having said that, a recently published post hoc mediation analysis of the EMPA-REG OUTCOME trial revealed that BP made a negligible contribution to the risk reduction of CV death with empagliflozin versus placebo, thus raising more questions on the probable multifaceted nature of empagliflozin’s effects on CV outcomes.

Effects on diuresis and RAAS
The diuretic effect of SGLT2 inhibitors has been examined and considered a possible mechanism during EMPA-REG OUTCOME, as SGLT2 inhibitors exhibit some similarities with loop diuretics. SGLT2 inhibitors cause a prolonged reduction in extracellular fluid and plasma volume, which reduces cardiac preload and – as with reduced afterload – results in lower cardiac work and oxygen consumption. In addition, the depletion of sodium by SGLT2 inhibitor-related diuresis is assumed to contribute to the elevated hematocrit. Hematopoiesis may also have a role, as small increases in reticulocytes, red cell mass, and erythropoietin have been reported during SGLT2 inhibitor treatment. The recent EMPA-REG OUTCOME trial post hoc mediation analysis already mentioned reported that changes in hematocrit and hemoglobin (ie, volume-related factors) appeared to be important mediators of CV mortality risk reduction.

Hematocrit
Increased hematocrit was reported during EMPA-REG OUTCOME, and has been observed during other trials of SGLT2 inhibitor treatment. Hemoconcentration following SGLT2 inhibitor-related diuresis is assumed to contribute to the elevated hematocrit. Hematopoiesis may also have a role, as small increases in reticulocytes, red cell mass, and erythropoietin have been reported during SGLT2 inhibitor treatment. The recent EMPA-REG OUTCOME trial post hoc mediation analysis already mentioned reported that changes in hematocrit and hemoglobin (ie, volume-related factors) appeared to be important mediators of CV mortality risk reduction.

Effects on RAAS
The activity of RAAS during clinical studies of SGLT2 inhibitors was found to be slightly increased but within
normal parameters, indicating a possible compensatory response to the resulting reductions in intravascular volume and BP. It has been suggested, however, that empagliflozin may act via non-classic RAAS pathways and that this may explain the decreased risk of CV events during EMPA-REG OUTCOME. It is hypothesized that instead of acting via the type 1 angiotensin II (T1-AT2) receptor, which contributes to the pathogenesis of CVD, empagliflozin may increase activation of the type 2 angiotensin II (T2-AT2) receptor and Mas-receptor pathways, which cause cardio-protective responses (eg, vasodilation, anti-inflammatory effects, and positive inotropic effects). Although ~80% of patients received ACE inhibitors or T1-AT2 receptor blockers during EMPA-REG OUTCOME, empagliflozin could have had additive cardioprotective effects via non-classic RAAS pathways.

Renal effects

Given the link between CVD and renal dysfunction in T2DM, renal effects are likely to influence CV outcomes. SGLT2 inhibition was shown to improve renal outcomes with empagliflozin in EMPA-REG OUTCOME. Specifically, reductions in relative risk for empagliflozin versus placebo groups were observed for incident or worsening nephropathy, progression to macroalbuminuria, doubling of serum creatinine levels, and initiation of renal replacement therapy. Renal outcomes were not viewed as statistically significant in the CANVAS Program, but potential renal benefits associated with canagliflozin versus placebo included decreased progression to albuminuria, and a reduction in the renal composite endpoint (sustained 40% reduction in eGFR, need for renal-replacement therapy, or renal death). The renal protection mechanisms are likely to be multifactorial; SGLT2 inhibition reduces proximal tubular sodium reabsorption and increases delivery of sodium to the macula densa, and it has been postulated that this may restore tubuloglomerular feedback, resulting in changes that decrease renal blood flow and reduce glomerular hyperfiltration and intraglomerular pressure. Clinically, these effects may be manifested as acute reductions in albuminuria and eGFR, followed by longer term eGFR stability. However, it should be noted that the patient populations of these CVOTs were likely to be in the more advanced stages of diabetes (EMPA-REG OUTCOME, 57.0% and 25.1% of patients were diagnosed with T2DM for >10 years and >5–10 years, respectively; CANVAS Program, mean duration of T2DM was 13.5 years), thus glomerular hyperfiltration – which generally occurs early in the natural history of diabetes, before diabetic kidney disease progresses to its later stages, where glomerular filtration eventually decreases – would be less likely to occur.

Inflammation

The significance of inflammation in the development of atherosclerosis is well known, and diabetes is associated with systemic inflammation that causes endothelial dysfunction and contributes to atherosclerosis. However, as stated previously herein, the CV benefits observed during EMPA-REG OUTCOME do not appear presently to be closely related to effects on atherosclerosis. Nevertheless, experimental models have demonstrated that SGLT2 inhibition decreased expression of inflammatory markers in mouse plasma and liver tissue, and reduced oxidative stress associated with hyperglycemia in rat kidney and mouse aortic endothelium. This may be secondary to increased fatty acid oxidation caused by a shift in the substrate for energy metabolism (ie, from carbohydrate to lipid). However, the contribution of any potential anti-inflammatory actions of SGLT2 inhibitors on the effects observed during EMPA-REG OUTCOME is currently unknown, as clinical evidence is lacking. A preliminary clinical trial to investigate the role of empagliflozin on oxidative stress is underway.

Nitric oxide

Increased oxidative stress and reduced nitric oxide bioavailability play a significant causal role in the endothelial dysfunction observed in patients with diabetes, which in turn contributes to the pathogenesis of atherosclerosis. Hyperglycemia and/or advanced glycosylation end products inhibit nitric oxide synthase, thus reducing the levels of nitric oxide and its protective effect against atherosclerosis. Improved glucose control in T2DM that is associated with SGLT2 inhibitor action and reduction in oxidative stress may help restore nitric oxide levels and have a favorable effect on CV outcomes. However, given that the benefits to CV risk observed during EMPA-REG OUTCOME do not currently appear to be closely related to effects on atherosclerosis, any potential effects pertaining to nitric oxide need further investigation.

Glucagon effects

Glucagon is known to regulate cardiac glucose utilization and modulate cardiac function with positive inotropic and anti-arrhythmogenic effects. Increased blood glucagon levels were associated with empagliflozin treatment; possibly due to the associated glucose excretion (as demonstrated in patients with T2DM using tracer techniques) and/or...
potentially via a direct effect on pancreatic alpha cells (as elucidated from human and animal cell cultures). It is possible that the reduced risks of heart failure and CV death reported during EMPA-REG OUTCOME may be partly explained by enhanced myocardial function and decreased rhythm disturbances, respectively, related to increased levels of glucagon.

**SGLT1 inhibition**

As SGLT2 inhibitors show some degree of binding to SGLT1 receptors, these agents could have an effect on tissue other than the kidney where SGLT1 expression occurs, such as the intestine, liver, lung, and heart. This is illustrated by the action of sotagliflozin, a first-in-class inhibitor of both SGLT2 and SGLT1, in which SGLT1 inhibition leads to a reduction in intestinal glucose absorption in addition to the increase in urinary glucose excretion mediated by SGLT2 inhibition (and, to a lesser extent, SGLT1 inhibition). Recent animal data suggest that SGLT1 provides an important protective mechanism against ischemia reperfusion injury by enhancing cardiac energy metabolism; hence, differences in cardiac SGLT1 selectivity may potentially explain the differences in mortality results between the CVOTs. Empagliflozin has relatively high selectivity for SGLT2 over SGLT1 and, therefore, should not inhibit SGLT1 (inhibitor concentration at half-maximal response [nM]: empagliflozin, 3.1 for SGLT2 and 8300 for SGLT1 [>2500-fold selectivity]; dapagliflozin, 1.2 for SGLT2 and 1400 for SGLT1 [>1200-fold selectivity]; canagliflozin, 2.7 for SGLT2 and 710 for SGLT1 [>250-fold selectivity]).

**Conclusion**

Recently reported CVOTs involving canagliflozin and other CV outcomes data for SGLT2 inhibitors support the CV benefits of these agents in T2DM, as originally observed with empagliflozin during the EMPA-REG OUTCOME trial. In view of the relatively short time in which CV benefits were demonstrated during EMPA-REG OUTCOME, the underlying process appears to be unrelated to changes in the development or progression of atherosclerosis. Most clinical commentators agree that the mechanism is likely to be multifactorial and may include hemodynamic effects, such as reductions in BP and intravascular volume, as well as metabolic effects, such as changes in adiposity and fuel energetics. Other factors may warrant further investigation, such as possible effects on inflammation and nitric oxide, as well as potential CV and metabolic effects of increased glucagon release. Additional studies to determine whether SGLT2 inhibitors have a broader role in the treatment of heart failure are underway, as are studies to investigate the role of these agents in atherosclerosis (Table 5).

However, further questions may now arise following a recent exploratory investigation into potential mediators of the reduction in risk of CV death with empagliflozin versus placebo during the EMPA-REG OUTCOME trial, in which it was reported that changes in some traditional CV risk factors (including obesity, BP, lipids, and renal function) made negligible contributions, whereas changes in volume-related factors (hematocrit and hemoglobin) appeared to be important mediators of the reduction in CV mortality risk. Furthermore, although alluded to in the CANVAS Program and CVD-REAL trials, dedicated randomized controlled studies to investigate the

---

**Table 5** Clinical trials of sodium glucose cotransporter 2 inhibitors that are underway to investigate heart failure or atherosclerosis

<table>
<thead>
<tr>
<th>Agent and indication</th>
<th>Trial name and details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canagliflozin + heart failure</td>
<td>Treatment of Diabetes in Patients With Systolic Heart Failure <a href="https://clinicaltrials.gov/ct2/show/NCT02920918">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Dapagliflozin + heart failure</td>
<td>Dapagliflozin in Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF) <a href="https://clinicaltrials.gov/ct2/show/NCT03030235">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Empagliflozin + heart failure</td>
<td>Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF) <a href="https://clinicaltrials.gov/ct2/show/NCT03036124">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Canagliflozin + heart failure</td>
<td>Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure (DEFINE-HF) <a href="https://clinicaltrials.gov/ct2/show/NCT02653482">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Dapagliflozin + atherosclerosis</td>
<td>Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes (REFORM) <a href="https://clinicaltrials.gov/ct2/show/NCT02397421">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Empagliflozin + heart failure</td>
<td>EMPagliflozin outcomeE RiAl in Patients With chronIc hearT Failure With Reduced Ejection Fraction (EMPEROR-Reduced) <a href="https://clinicaltrials.gov/ct2/show/NCT03057977">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Dapagliflozin + atherosclerosis</td>
<td>EMPagliflozin outcomeE RiAl in Patients With chronIc hearT Failure With Preserved Ejection Fraction (EMPEROR-Preserved) <a href="https://clinicaltrials.gov/ct2/show/NCT03057951">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Empagliflozin + atherosclerosis</td>
<td>Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide <a href="https://clinicaltrials.gov/ct2/show/NCT02610088">Clinical trials.gov</a></td>
</tr>
<tr>
<td>Empagliflozin + atherosclerosis</td>
<td>Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial <a href="https://clinicaltrials.gov/ct2/show/NCT02610088">Clinical trials.gov</a></td>
</tr>
</tbody>
</table>

**Note:** Clinical trial registry website (US National Institutes of Health); citation listed if study details have been published.
effect of SGLT2 inhibitors in the primary prevention of CVD are also needed. Clinicians await the results from further CVOTs of SGLT2 inhibitors, which when published will add to the evidence base in determining the clinical role of this drug class in reducing CV risk in patients with T2DM.

Author contributions

All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure

T.S.C. receives speaker’s bureau and/or consultant fees from Dexcom, Sanofi, Novo Nordisk, and Valeritas. J.P. receives speaker’s bureau fees and consulting fees from Insulet, Sanofi, and Valeritas, and consulting fees from Dexcom, MannKind, and Novo Nordisk. Medical writing assistance, supported financially by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPi), was provided by Geraldine Thompson, PhD, Jennifer Garrett, MB BS, and Debra Brocksmith, MB ChB, PhD, of Envision Scientific Solutions during the preparation of this manuscript. BIPi was given the opportunity to review the data used in the manuscript for factual accuracy only. The authors report no other conflicts of interest in this work.

References


Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018:11
submit your manuscript | www.dovepress.com
Dovepress
Dovepress


